DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Aricept (Donepezil Hydrochloride) - Summary



ARICEPT® (donepezil hydrochloride) is a reversible inhibitor of the enzyme acetylcholinesterase.

ARICEPT® is indicated for the treatment of mild to moderate dementia of the Alzheimer's type.

See all Aricept indications & dosage >>


Media Articles Related to Aricept (Donepezil)

ARICEPT (Donepezil) effective for severe Alzheimer's disease
Source: The Doctors Lounge - Neurology
Donepezil reverses some aspects of cognitive deterioration seen in severe Alzheimer's disease.

Investigational Drug Added to Donepezil Shows Promise in AD
Source: Medscape NeurologyHeadlines [2015.07.24]
Adding 5-HT6 receptor antagonist RVT-101 to standard therapy with donepezil in adults with mild to moderate Alzheimer's disease resulted in improved cognition and function.
Medscape Medical News

Donepezil Add-On Promising in Completer Analysis
Source: MedPage Today Neurology [2015.07.22]
(MedPage Today) -- Serotonin modulator slows but doesn't stop cognitive decline in phase II re-analysis.

Positive initial phase 2a study data with ANAVEX 2-73 showing early evidence of improving cognition in patients with Alzheimer's disease
Source: Clinical Trials / Drug Trials News From Medical News Today [2015.07.24]
Anavex Life Sciences Corp. has announced initial positive cognitive data for ANAVEX 2-73, the Company's lead investigational oral treatment for Alzheimer's targeting sigma-1 and muscarinic...

New data presented from phase 1b study of investigational Alzheimer's disease treatment Aducanumab (BIIB037)
Source: Clinical Trials / Drug Trials News From Medical News Today [2015.07.24]
Today Biogen has announced new results from a prespecified interim analysis of PRIME, the Phase 1b placebo-controlled study of aducanumab (BIIB037) in patients with prodromal or mild Alzheimer's...

more news >>

Published Studies Related to Aricept (Donepezil)

Evaluation of an 8-item Severe Impairment Battery (SIB-8) vs. the full SIB in moderate to severe Alzheimer's disease patients participating in a donepezil study. [2013]
explored the SIB-8 scale with respect to its validity and sensitivity... CONCLUSIONS: In this post hoc analysis, similar treatment effects were measured

Ventricular enlargement and its clinical correlates in the imaging cohort from the ADCS MCI donepezil/vitamin E study. [2013]
We analyzed the baseline and 3-year T1-weighted magnetic resonance imaging data of 110 amnestic mild cognitive impairment (MCI) participants with minimal hippocampal atrophy at baseline from the Alzheimer's Disease Cooperative Study group MCI Donepezil/Vitamin E trial... Executive decline was associated with right frontal and left temporal horn enlargement.

Donepezil and memantine for moderate-to-severe Alzheimer's disease. [2012]
disease... CONCLUSIONS: In patients with moderate or severe Alzheimer's disease, continued

Pilot randomized trial of donepezil hydrochloride for delirium after hip fracture. [2011.11]
OBJECTIVES: To determine whether donepezil hydrochloride can reduce the prevalence and severity of delirium in older adults undergoing hip fracture repair... CONCLUSION: Participants randomized to donepezil had no significant improvement in delirium presence or severity but experienced more side effects. Overall, sufficient evidence was not found from this pilot study to warrant a definitive Phase III trial. (c) 2011, Copyright the Authors Journal compilation (c) 2011, The American Geriatrics Society.

Combination treatment in Alzheimer's disease: results of a randomized, controlled trial with cerebrolysin and donepezil. [2011.08]
Treatment with neurotrophic agents might enhance and/or prolong the effects of cholinesterase inhibitors (ChEIs) in Alzheimer's disease (AD)...

more studies >>

Clinical Trials Related to Aricept (Donepezil)

Aricept to Improve Functional Tasks in Vascular Dementia [Recruiting]
Medications for memory improvement are available but they may not actually improve the ability to do real world tasks. The purpose of this research study is to determine if a medicine used to treat memory problems donepezil(Aricept) enhances the ability to remember steps of functional tasks and the actual ability to perform tasks relevant to real-life independence. Aricept is an FDA approved medication for the treatment of Alzheimer's disease. Aricept is an investigational drug for the purposes of this study, and is not approved for this purpose.

Double-blind Study of E2020 in Patients With Dementia With Lewy Bodies - Phase II [Recruiting]
The purpose of this study is to evaluate the efficacy and safety of E2020 in patients with Dementia with Lewy Bodies (DLB).

Efficacy and Safety of Aricept in the Treatment of Severe Alzheimer’s Disease [Completed]
Donepezil hydrochloride (Aricept) has been approved to treat symptoms associated with mild to moderate Alzheimer’s disease (AD). Aricept has been shown to improve the memory and thinking abilities, activities of daily living and global function in patients. The purpose of the study is to further investigate the effectiveness and safety of donepezil in patients with severe Alzheimer’s disease.

Donepezil is thought to work in the brain by increasing the levels of an important brain chemical called acetylcholine. This chemical helps a person’s memory to work better.

Compare the Efficacy and Safety of Donepezil Hydrochloride 23 mg Treatment With Continuation of Donepezil Hydrochloride 10 mg Treatment in Japanese Subjects With Severe Alzheimer's Disease [Recruiting]
The purpose of this study is to compare 23 mg donepezil sustained release to the currently marketed formulation of 10 mg donepezil immediate release in patients with severe Alzheimer's disease.

Multi-centre UK Study of the Acetylcholinesterase Inhibitor Donepezil in Early Dementia Associated With Parkinson's Disease [Not yet recruiting]
To demonstrate the superiority of donepezil over placebo in improving cognitive function, neuropsychiatric burden and functional ability in people with Parkinson's disease and mild dementia after 24 months of treatment.

To demonstrate the superiority of donepezil over placebo in improving patient and carer quality of life and to establish the cost-effectiveness of donepezil.

more trials >>

Reports of Suspected Aricept (Donepezil) Side Effects

Syncope (31)Electrocardiogram QT Prolonged (26)Convulsion (25)Drug Interaction (24)Fall (22)Altered State of Consciousness (21)Bradycardia (20)Dementia (19)Vomiting (19)Loss of Consciousness (18)more >>


Based on a total of 9 ratings/reviews, Aricept has an overall score of 4.67. The effectiveness score is 5.56 and the side effect score is 6.44. The scores are on ten point scale: 10 - best, 1 - worst. Below are selected reviews: the highest, the median and the lowest rated.

Aricept review by care giver of 69 year old male patient

Overall rating:  
Effectiveness:   Considerably Effective
Side effects:   No Side Effects
Treatment Info
Condition / reason:   Alzheimers
Dosage & duration:   5g for one month rising to 10g (dosage frequency: daily) for the period of 3 months total - and on-going
Other conditions:   None
Other drugs taken:   None
Reported Results
Benefits:   Only moderate improvements noted on the 5g dosage. Improvements much more noticeable at 10g - or after 30 days of taking medication. Less confusion, more awareness in social surroundings, more outward and positive in attitude.
Side effects:   So far no negative noted
Comments:   Take one pill in the morning. Also vitamin supplements (Multi-vitamin, brain-booster vitamin, and homo-cysteine level reducer)


Aricept review by care giver of 80 year old female patient

Overall rating:  
Effectiveness:   Ineffective
Side effects:   Mild Side Effects
Treatment Info
Condition / reason:   Alzheimer's disease
Dosage & duration:   10 mg taken once daily for the period of 6 months
Other conditions:   hernia, teeth problems
Other drugs taken:   Tamasapan
Reported Results
Benefits:   We could not identify any benefits at all. The behavior and memory problems remained unchanged or worsened over time. Anxiety continued to increase and the dementia progressed systematically. Disorientation continued to increase and the patient became more and more difficult to manage. It appeared that irritability increased and the patient became more agitated more easily.
Side effects:   There was some indication that there was at least some increase nausa as well as some infrequent but increased bouts of diarrhea. There were a few episodes of vomiting, but it might be attributed to other factors for this one side effect. There was definitely increased insomnia as well as loss of appetite, but it can not be definitively stated that the drug alone contributed to these although it did occur after the drug was begun.
Comments:   The patient was given a daily dose. After transfer to a care facility, the regimentation in taking the dose was firmly set in place. Staff medical personnel on site did not observe any benefits, and as a result, after about 6 months the prescription was terminated. During the time the drug was used, there was a patient review every other week to ascertain whether there seemed to be any improvement in the patient. Memory tests were administered and one-on-one interviews were executed by medical personnel. The results of the memory testing showed no net improvement nor was there any identifiable changes that might be considered positive. Ultimately her psychiatrist in consultation with the family decided that the drug did not seem to provide any net gain.


Aricept review by care giver of 67 year old female patient

Overall rating:  
Effectiveness:   Ineffective
Side effects:   Severe Side Effects
Treatment Info
Condition / reason:   short term memory loss
Dosage & duration:   5 mg taken once for the period of once
Other conditions:   severe head pain, feel like throwing up
Other drugs taken:   welbutrin
Reported Results
Benefits:   none, only took one pill and found that the side effects do not warrant continued use.
Side effects:   severe head pain, feel like throwing up, felt lousy for 12 hours after taking first pill.
Comments:   Will not take pill again. The side effects of loosing a nights sleep, having severe head pain, and feeling like throwing up will result in not taking another pill as this drug does not agree with patient.

See all Aricept reviews / ratings >>

Page last updated: 2015-07-24

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2015